In the past week, TNXP stock has gone down by -12.39%, with a monthly gain of 66.75% and a quarterly surge of 146.70%. The volatility ratio for the week is 4.43%, and the volatility levels for the last 30 days are 8.86% for Tonix Pharmaceuticals Holding Corp The simple moving average for the past 20 days is -2.83% for TNXP’s stock, with a 58.66% simple moving average for the past 200 days.
Is It Worth Investing in Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) Right Now?
TNXP has 36-month beta value of 2.10. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TNXP is 7.32M, and currently, short sellers hold a 14.43% ratio of that float. The average trading volume of TNXP on June 12, 2025 was 1.20M shares.
TNXP) stock’s latest price update
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP)’s stock price has decreased by -10.77 compared to its previous closing price of 37.71. However, the company has seen a -12.39% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-10 that CHATHAM, N.J., June 10, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D.
Analysts’ Opinion of TNXP
ROTH Capital, on the other hand, stated in their research note that they expect to see TNXP reach a price target of $4. The rating they have provided for TNXP stocks is “Buy” according to the report published on April 18th, 2019.
ROTH Capital gave a rating of “Buy” to TNXP, setting the target price at $6 in the report published on August 18th of the previous year.
TNXP Trading at 37.15% from the 50-Day Moving Average
After a stumble in the market that brought TNXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.48% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TNXP starting from LEDERMAN SETH, who purchase 4,000 shares at the price of $21.55 back on May 15 ’25. After this action, LEDERMAN SETH now owns 4,005 shares of Tonix Pharmaceuticals Holding Corp, valued at $86,200 using the latest closing price.
Stock Fundamentals for TNXP
Current profitability levels for the company are sitting at:
- -7.22 for the present operating margin
- 0.3 for the gross margin
The net margin for Tonix Pharmaceuticals Holding Corp stands at -11.46. The total capital return value is set at -0.4. Equity return is now at value -91.44, with -80.39 for asset returns.
Based on Tonix Pharmaceuticals Holding Corp (TNXP), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -105.64.
Currently, EBITDA for the company is -74.94 million with net debt to EBITDA at 1.86. When we switch over and look at the enterprise to sales, we see a ratio of 11.41. The receivables turnover for the company is 3.03for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.31.
Conclusion
To put it simply, Tonix Pharmaceuticals Holding Corp (TNXP) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
